Rabies Human Monoclonal Antibody

Rabies human monoclonal antibody is a laboratory-produced antibody preparation used to provide immediate, temporary passive protection after potential exposure to rabies virus. Unlike a vaccine, which stimulates the body's immune system to develop its own response over time, a monoclonal antibody supplies antibodies that can bind to and neutralise the virus. The Indian product Rabishield contains a recombinant, fully human immunoglobulin G1 monoclonal antibody directed against the rabies virus glycoprotein, which is important for viral attachment and entry into host cells. By binding to this protein, the antibody helps neutralise virus at the exposure site before infection becomes established. It is used as part of rabies post-exposure prophylaxis (PEP), particularly for eligible people with severe exposures, such as bites or scratches that meet World Health Organization Category III criteria. Administration generally involves infiltration into and around the wounds, according to the product's approved instructions. Rabies monoclonal antibody does not replace rabies vaccination or thorough wound cleansing; these measures work together to reduce the risk of disease. Product formulations and dosing differ, so the instructions for the specific authorised preparation must be followed. Prompt medical assessment is essential because clinical rabies is almost invariably fatal, while timely, appropriate post-exposure prophylaxis can prevent it.

Rabies monoclonal antibodies were developed as alternatives to human or equine rabies immunoglobulin for passive immunisation after exposure. These recombinant antibodies target rabies virus glycoprotein, helping neutralise the virus at the wound site. Rabishield, developed by Serum Institute of India, is a fully human monoclonal antibody preparation and received regulatory approval in India in 2016 for use as the passive-antibody component of rabies post-exposure prophylaxis. Clinical studies have compared this preparation with human rabies immunoglobulin, while later phase IV research in India evaluated safety and immune responses when it was combined with rabies vaccine. A phase IV trial published in The Lancet in 2025 reported that the Rabishield-containing regimen was well tolerated and that no participants developed rabies during the one-year follow-up. Regulatory authorisation is product- and country-specific; an Indian approval should not be interpreted as FDA or EMA approval. Clinicians should verify current national authorisation and the approved product information before use.

Rabies human monoclonal antibody is used for passive immunisation as part of post-exposure prophylaxis in people assessed as having a qualifying potential rabies exposure. It is particularly relevant to Category III exposures, including transdermal bites or scratches, saliva contamination of broken skin or mucous membranes, and other exposures classified as severe under applicable guidelines. The antibody is administered with an appropriate rabies vaccine regimen in people who require both passive and active immunisation. It is not a treatment for established clinical rabies and should not be used as a substitute for wound cleansing or vaccination. Eligibility depends on the exposure category, previous rabies vaccination, the specific product's approved indication, and national guidance. Previously vaccinated individuals generally follow a different post-exposure regimen and ordinarily do not require rabies immunoglobulin or monoclonal antibody. A qualified healthcare professional should assess the exposure promptly and determine the required prophylaxis.

For Rabishield, the manufacturer's recommended dose is 3.33 IU/kg body weight, administered as a single dose for post-exposure prophylaxis. As much of the calculated dose as anatomically feasible should be infiltrated carefully into and around all wounds. Any remaining volume should be handled according to the current product instructions; the Rabishield manufacturer's information directs that it be administered intramuscularly at a site distant from rabies vaccine administration. Dilution, when necessary to cover multiple wounds, must follow the product-specific instructions and appropriate clinical guidance. The antibody should be given promptly as part of the post-exposure regimen and alongside rabies vaccination when indicated. Vaccine schedules vary by route and national guidance; the full recommended course must be completed. The antibody is not routinely repeated as part of the same exposure regimen. Administration should be performed by trained healthcare professionals, with attention to wound anatomy, correct dose calculation, separate vaccine administration sites, and documentation of the exposure and treatment.

Reported adverse effects with rabies monoclonal antibody-containing post-exposure regimens have generally been mild or moderate. They may include pain, tenderness, redness or swelling at the injection or wound-infiltration site, as well as symptoms such as headache, fever or general discomfort. Some reactions observed during post-exposure prophylaxis may also be associated with the rabies vaccine or the exposure itself, so the cause should be assessed clinically. Available Indian post-marketing safety data for Rabishield combined with rabies vaccine found that most reported events were mild and resolved without lasting effects. Individual responses vary, and not everyone experiences side effects. Patients should inform their healthcare professional about persistent or worsening symptoms, and any suspected adverse reaction should be assessed and documented. Medical staff should provide clear instructions about when to seek urgent care, particularly if symptoms suggest a severe allergic reaction.

Serious reactions appear uncommon in available studies, but hypersensitivity, including a severe allergic reaction, remains an important potential risk with biological products. Administration should take place in a setting where the patient can be assessed and appropriate emergency treatment is available. The product must be administered by the recommended route; it should not be injected intravenously. Rabies monoclonal antibody is intended to prevent infection after exposure and is not effective as treatment for symptomatic clinical rabies. Incorrect dose calculation, incomplete infiltration of accessible wounds, delayed prophylaxis or failure to complete vaccination may compromise protection. It is important not to exceed the recommended dose or administer additional passive antibody without clinical justification, as this may interfere with the immune response to rabies vaccination. A history of serious hypersensitivity to the specific product or its ingredients requires assessment against the approved product information. Suspected severe adverse reactions should be managed promptly and reported through the applicable pharmacovigilance system.

A careful exposure history should establish the type, location and timing of the bite, scratch or other contact, the animal involved, and any previous rabies vaccination or post-exposure treatment. Wounds should be washed and flushed thoroughly with soap and running water as soon as possible, with appropriate antiseptic treatment where available. Pregnancy, breastfeeding, childhood and older age should be assessed in context, but the urgency of indicated rabies prophylaxis should not be overlooked. The patient's history of severe allergy and any previous reaction to a similar product should be reviewed. Rabies monoclonal antibody is a biological product, so classic metabolic drug interactions are not generally expected; however, its administration must be coordinated with rabies vaccine and any other passive antibody product. Unnecessary additional rabies immunoglobulin or monoclonal antibody should be avoided. The antibody and vaccine should be administered at separate sites according to product instructions. Immunocompromised patients may require additional assessment and follow-up under current rabies guidance. Product-specific storage, handling, expiry and cold-chain requirements must be followed.

Treat suspected rabies exposure as urgent and arrange prompt assessment rather than delaying prophylaxis while waiting for symptoms or unnecessary investigations. Verify the exposure category, prior vaccination history, product name, concentration and weight-based dose before preparation. For Rabishield, calculate the dose using the labelled potency of 3.33 IU/kg, and infiltrate the calculated amount into and around all accessible wounds as anatomically feasible. Follow the current manufacturer's instructions for any remaining volume and for dilution when multiple wounds require coverage. Do not assume that dosing instructions for one rabies monoclonal antibody product apply to another formulation. Ensure that appropriate rabies vaccine is administered according to the recommended schedule, using a separate site and syringe. Document the animal exposure, wound assessment, antibody dose, infiltration sites, vaccine schedule and counselling provided. Observe the patient as clinically appropriate after administration and ensure that staff can recognise and manage hypersensitivity. Explain the importance of completing vaccination and returning promptly if new exposure information or adverse symptoms arise. Pharmacists should verify product integrity, storage conditions, expiry and local regulatory status before dispensing or administration.